Molecular Mechanisms of Drug Resistance in Leishmania spp.
Pathogens · 27.09.2024 · 13 (10) · 835
DOI: 10.3390/pathogens13100835 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 27.09.2024. Verfasst von Maria Juliana Moncada-Diaz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Biochemistry, Texas Tech University Health Science Center, Lubbock, TX 79430, USA. Hauptthemen laut MEDLINE: Leishmania, Drug Resistance, Leishmaniasis, Antiprotozoal Agents. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Start-up fund from the Texas Tech University Health Sciences Center (TTUHSC), Texas Tech University Health Sciences Center (TTUHSC).
Abstract (Originalsprache)
The protozoan parasite Leishmania causes leishmaniasis, a neglected tropical disease, that disproportionately affects underdeveloped countries. This disease has major health, economic, and social implications, particularly because of the limited treatment options, high cost, the severe side effects associated with available therapeutics, and the high rate of treatment failure caused by the parasites’ growing resistance to current medications. In this review, we describe first the common strategies used by pathogens to develop drug resistance and then focus on the arsenal of available drugs to treat leishmaniasis, their modes of action, and the molecular mechanisms contributing to drug resistance in Leishmania spp., including the role of genomic, transcriptional, and translational control. We focus more specifically on our recent discovery of translational reprogramming as a major driver of drug resistance leading to coordinated changes in the translation of transcripts and orchestrating changes in metabolome and lipidome to support drug resistance. A thorough understanding of these mechanisms is essential to identify the key elements needed to combat resistance and improve leishmaniasis treatment methods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology and Biochemistry, Texas Tech University Health Science Center, Lubbock, TX 79430, USA.
- Department of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA.
- Programa de Estudio y Control de Enfermedades Tropicales-PECET, Facultad de Medicina, Universidad de Antioquia, Medellín 050010, Colombia.
ORCID-Profile: Maria Juliana Moncada-Diaz, Cristian Camilo Rodríguez-Almonacid, Eyson Quiceno-Giraldo, Francis T H Khuong, Carlos Muskus, Zemfira N Karamysheva
Förderung
- Start-up fund from the Texas Tech University Health Sciences Center (TTUHSC)
- Texas Tech University Health Sciences Center (TTUHSC)
Zitieren
APA
Moncada-Diaz, M. J., Rodríguez-Almonacid, C. C., Quiceno-Giraldo, E., Khuong, F. T. H., Muskus, C., & Karamysheva, Z. N. (2024). Molecular Mechanisms of Drug Resistance in Leishmania spp. Pathogens, 13(10), 835. https://doi.org/10.3390/pathogens13100835
Vancouver
Moncada-Diaz MJ, Rodríguez-Almonacid CC, Quiceno-Giraldo E, Khuong FTH, Muskus C, Karamysheva ZN. Molecular Mechanisms of Drug Resistance in Leishmania spp. Pathogens. 2024;13(10):835. doi:10.3390/pathogens13100835
BibTeX
@article{MoncadaDiaz2024,
author = {Moncada-Diaz, Maria Juliana and Rodríguez-Almonacid, Cristian Camilo and Quiceno-Giraldo, Eyson and Khuong, Francis T H and Muskus, Carlos and Karamysheva, Zemfira N},
title = {Molecular Mechanisms of Drug Resistance in Leishmania spp},
journal = {Pathogens},
year = {2024},
volume = {13},
number = {10},
pages = {835},
doi = {10.3390/pathogens13100835}
}
EUVIMED